Homatropine
Equipin, Homapin, Homatropine Methylbromide / Hydrocodone, Hycodan (homatropine) is a small molecule pharmaceutical. Homatropine was first approved as Homapin-10 on 1982-01-01. It is used to treat inflammation in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Combinations
Hycodan, Hydrocodone homatropine methylbromide (discontinued: Homatropine methylbromide hydrocodone, Hydrocodone homatropine methylbromide, Hydropane, Tussigon)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Homatropine methylbromide
+
Hydrocodone bitartrate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| HYCODAN | Genus Lifesciences | N-005213 RX | 1988-07-26 | 2 products, RLD |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| homatropine hydrobromide ophthalmic | unapproved drug other | 2022-10-28 |
| hycodan | New Drug Application | 2021-12-29 |
| hydrocodone bitartrate and homatropine methylbromide | NDA authorized generic | 2024-08-05 |
| hydrocodone bitartrate and homatropine methylbromide syrup | ANDA | 2009-09-21 |
| hydromet | ANDA | 2024-05-31 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A03: Drugs for functional gastrointestinal disorders
— A03B: Belladonna and derivatives containing drugs, plain for functional gastrointestinal disorders
— A03BB: Belladonna alkaloids, semisynthetic, quaternary ammonium compounds for functional gastrointestinal disorders
— A03BB06: Homatropine methylbromide
— A03C: Antispasmodics in combination with psycholeptics
— A03CB: Belladonna and derivatives in combination with psycholeptics
— A03CB04: Homatropine methylbromide and psycholeptics
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01F: Mydriatics and cycloplegics
— S01FA: Anticholinergic mydriatics and cycloplegics
— S01FA05: Homatropine
HCPCS
No data
Clinical
Clinical Trials
195 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pain | D010146 | EFO_0003843 | R52 | 4 | 9 | 11 | 8 | 5 | 37 |
| Postoperative pain | D010149 | — | G89.18 | 5 | 1 | 9 | 13 | 6 | 34 |
| Acute pain | D059787 | — | R52 | 4 | 8 | 6 | 1 | 1 | 20 |
| Low back pain | D017116 | HP_0003419 | M54.5 | — | 2 | 9 | 2 | 2 | 15 |
| Back pain | D001416 | HP_0003418 | M54 | — | 2 | 10 | 2 | 1 | 15 |
| Chronic pain | D059350 | HP_0012532 | — | — | 2 | 5 | 2 | 3 | 12 |
| Vomiting | D014839 | HP_0002013 | R11.1 | — | — | 4 | 1 | 3 | 8 |
| Nausea | D009325 | HP_0002018 | R11.0 | — | — | 4 | 1 | 3 | 8 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | 2 | 3 | 2 | — | 7 |
| Bone fractures | D050723 | EFO_0003931 | T14.8 | 1 | — | — | 4 | 1 | 6 |
Show 53 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Shoulder pain | D020069 | HP_0030834 | M25.51 | — | — | 2 | — | 2 | 4 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | — | 1 | — | 1 | 3 |
| Anterior cruciate ligament injuries | D000070598 | — | — | — | 1 | 2 | — | — | 2 |
| Head and neck neoplasms | D006258 | — | — | 1 | — | 1 | — | — | 2 |
| Mucositis | D052016 | EFO_1001898 | — | 1 | — | 1 | — | — | 2 |
| Tibial meniscus injuries | D000070600 | — | — | — | — | 1 | — | — | 1 |
| Multiple myeloma | D009101 | — | C90.0 | — | — | 1 | — | — | 1 |
| Lymphoma | D008223 | — | C85.9 | — | — | 1 | — | — | 1 |
| Nephrolithiasis | D053040 | — | N20.0 | — | — | 1 | — | — | 1 |
| Kidney calculi | D007669 | EFO_0004253 | N20 | — | — | 1 | — | — | 1 |
Show 10 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | 2 | 2 | — | — | 2 | 6 |
| Emergencies | D004630 | — | — | — | 1 | — | — | 2 | 3 |
| Musculoskeletal pain | D059352 | — | — | 1 | 1 | — | — | — | 2 |
| Corneal injuries | D065306 | HP_0000559 | — | — | 1 | — | — | — | 1 |
| Eye injuries | D005131 | — | S00-S09 | — | 1 | — | — | — | 1 |
| Back injuries | D019567 | — | — | — | 1 | — | — | — | 1 |
| Abdominal neoplasms | D000008 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 14 | — | — | — | — | 14 |
| Drug interactions | D004347 | — | — | 1 | — | — | — | 2 | 3 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | 2 | 3 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 2 | — | — | — | — | 2 |
| Liver diseases | D008107 | HP_0002910 | K70-K77 | 2 | — | — | — | — | 2 |
| Hepatic insufficiency | D048550 | — | — | 2 | — | — | — | — | 2 |
| Thyroid diseases | D013959 | HP_0000820 | E00-E07 | 1 | — | — | — | — | 1 |
| Parathyroid diseases | D010279 | — | E21.5 | 1 | — | — | — | — | 1 |
| Intervertebral disc degeneration | D055959 | HP_0008419 | — | 1 | — | — | — | — | 1 |
| Spondylolisthesis | D013168 | EFO_0007493 | M43.1 | 1 | — | — | — | — | 1 |
Show 4 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cancer pain | D000072716 | — | G89.3 | — | — | — | — | 2 | 2 |
| Personality disorders | D010554 | HP_0012075 | F60.6 | — | — | — | — | 2 | 2 |
| Hip fractures | D006620 | EFO_0003964 | S72.00 | — | — | — | — | 1 | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | — | 1 | 1 |
| Corneal diseases | D003316 | — | H18.9 | — | — | — | — | 1 | 1 |
| Intractable pain | D010148 | — | — | — | — | — | — | 1 | 1 |
| Femoracetabular impingement | D057925 | — | — | — | — | — | — | 1 | 1 |
| Obstetric labor complications | D007744 | — | — | — | — | — | — | 1 | 1 |
| Postpartum depression | D019052 | EFO_0007453 | F53.0 | — | — | — | — | 1 | 1 |
| Puerperal disorders | D011644 | EFO_0009683 | O89 | — | — | — | — | 1 | 1 |
Show 20 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Homatropine |
| INN | homatropine methylbromide |
| Description | Homatropine (Equipin, Isopto Homatropine) is an anticholinergic medication that is an antagonist at muscarinic acetylcholine receptors and thus the parasympathetic nervous system. It is used in eye drops as a cycloplegic (to temporarily paralyze accommodation), and as a mydriatic (to dilate the pupil).
|
| Classification | Small molecule |
| Drug class | atropine derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN1[C@H]2CC[C@@H]1C[C@H](OC(=O)C(O)c1ccccc1)C2 |
Identifiers
| PDB | — |
| CAS-ID | 87-00-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1618018 |
| ChEBI ID | 5747 |
| PubChem CID | 6321423 |
| DrugBank | DB00725 |
| UNII ID | 68JRS2HC1C (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Homatropine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Homatropine
+
Hydrocodone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,566 documents
View more details
Safety
Black-box Warning
Black-box warning for: Hycodan, Hydrocodone bitartrate and homatropine methylbromide, Hydromet
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
289 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use